Leaders in Pharmaceutical Business Intelligence (LPBI) Group

Archive for the ‘Biomarkers: Inflammation’ Category

Inflammation and potential links with the microbiome: Mechanisms of infection by SARS-CoV-2

Posted in Biomarkers: Inflammation, Coronavirus Gene Expression, COVID-19, Immune-Mediation (independent immunopathology: lung and reticuloendothelial system), Mechanisms of infection by SARS-CoV-2, Population Health Management, Genetics & Pharmaceutical, SARS-CoV-2, T-cell response to SARS-CoV-2 infection, Virus Infective Acute Respiratory Syndrome: SARS-CoV, tagged microbe–host interactionmicrobiomemiRNA on January 24, 2021| Leave a Comment »

Inflammation and potential links with the microbiome: Mechanisms of infection by SARS-CoV-2

Reporter: Aviva Lev-Ari, PhD, RN

Mechanisms of infection by SARS-CoV-2, inflammation and potential links with the microbiome

María Magdalena Aguirre García

Javier Mancilla-Galindo

Mercedes Paredes-Paredes

Álvaro Zamudio Tiburcio

Nydia Ávila-Vanzzini

Published Online:13 Jan 2021https://doi.org/10.2217/fvl-2020-0310

Human coronaviruses (HCoVs) were first isolated from patients with the common cold in the 1960s [1–3]. Seven HCoVs known to cause disease in humans have since been identified: HCoV-229E, HCoV-NL63, HCoV-OC43, HCoV-HKU1, the SARS coronavirus (SARS-CoV), the Middle East respiratory syndrome coronavirus and the novel SARS-CoV-2 [4]. The latter was identified after a spike in cases of pneumonia of unknown etiology in Wuhan, Hubei Province, China during December 2019 and was initially named novel coronavirus (2019-nCoV) [5,6]. The virus was renamed SARS-CoV-2 according to the International Committee on Taxonomy of Viruses classification criteria due to its genomic closeness to SARS-CoV; the disease caused by this virus was named coronavirus disease (COVID-19) according to the WHO criteria for naming emerging diseases [7]. SARS-CoV-2 belongs to the genera Betacoronavirus and shares a different degree of genomic similarity with the other two epidemic coronaviruses: SARS-CoV (∼79%) and Middle East respiratory syndrome coronavirus (∼50%) [8].

COVID-19 has caused considerable morbidity and mortality worldwide and has become the central phenomenon that is shaping our current societies. Human-to-human transmission is the main route of spread of the virus, mainly through direct contact, respiratory droplets and aerosols [9–12]. Management of COVID-19 has been extremely challenging due to its high infectivity, lack of effective therapeutics and potentially small groups of individuals (i.e., asymptomatic or mild disease) rapidly spreading the disease [13–17]. Although research describing COVID-19 and the mechanisms of infection by SARS-CoV-2 and its pathogenesis has expanded rapidly, there is still much to be learnt. Important gaps in knowledge which remain to be elucidated are the dynamic and complex interactions between the virus and the host’s immune system, as well as the potential interspecies communications occurring between ecological niches encompassing distinct microorganisms in both healthy individuals and persons living with chronic diseases, and how these interactions could determine or modulate disease progression and outcomes.

In this review, we describe recent insights into these topics, as well as remaining questions whose answers will allow us to understand how interactions between the virus, the immune system and microbial components could possibly be related to disease states in patients with COVID-19, as well as existing studies of the microbiome in patients with COVID-19.

SOURCE

https://www.futuremedicine.com/doi/full/10.2217/fvl-2020-0310?utm_content=buffere03d4&utm_medium=social&utm_source=twitter.com&utm_campaign=buffer

Read Full Post »

Bradykinin Hypothesis: Potential Explanation for COVID-19

Posted in Biomarkers: Inflammation, Coronavirus Gene Expression, COVID-19, Immune-Mediation (independent immunopathology: lung and reticuloendothelial system), Population Health Management, Genetics & Pharmaceutical, SAR-Cov-2 a vasculotropic (blood vessels) RNA Virus, SARS-CoV-2, SARS-COV2 Hijacking the Complement and Coagulation Systems, Virus Infective Acute Respiratory Syndrome: SARS-CoV on September 8, 2020| Leave a Comment »

Bradykinin Hypothesis: Potential Explanation for COVID-19

Reporter: Aviva Lev-Ari, PhD, RN

 

UPDATED on 9/14/2020

First Randomized Trial Backs Safety of ACE and ARB Heart Drugs in COVID-19 Patients

BRACE CORONA trial presented in a Hot Line Session at ESC Congress 2020

September 8, 2020 – Heart patients hospitalized with COVID-19 (SARS-CoV-2) can safely continue taking angiotensin-converting enzyme (ACE) inhibitors and angiotensin receptor blockers (ARBs), according to the BRACE CORONA trial presented in a Hot Line session at the virtual European Society of Cardiology (ESC) Congress 2020.[1]

ACE inhibitors and ARBs are commonly taken by heart patients to reduce blood pressure and to treat heart failure. There is conflicting observational evidence about the potential clinical impact of ACE inhibitors and ARBs on patients with COVID-19.[2] Select preclinical investigations have raised concerns about their safety in patients with COVID-19. Preliminary data hypothesize that renin-angiotensin-aldosterone system (RAAS) inhibitors could benefit patients with COVID-19 by decreasing acute lung damage and preventing angiotensin-II-mediated pulmonary inflammation.

Given the frequent use of these agents worldwide, randomized clinical trial evidence is urgently needed to guide the management of patients with COVID-19.

SOURCE

https://www.dicardiology.com/content/first-randomized-trial-backs-safety-ace-and-arb-heart-drugs-covid-19-patients

Related ACE and ARB Content Related to COVID-19:

ESC Council on Hypertension Says ACE-I and ARBs Do Not Increase COVID-19 Mortality

AHA Explains Severe COVID-19 is Closely Associated With Heart Issues

 

The Voice of Dr. Justin D. Pearlman, MD, PhD, FACC

Justin D. Pearlman, MD, PhD, FACC – Scientific Expert & Key Opinion Leader on Cardiovascular Diseases, Cardiac Imaging & Complex Diagnosis in Cardiology: Senior Editor & Author

The BRACE CORONA TRIAL compared outcomes for COVID19 patients previously on ACE inhibitor or ARB of holding the medication for a month, or not, and saw no significant benefit from withholding either class of medication. The basis for specific concern is the fact that the COVID19 virus utilizes ACE2 receptors for its invasion, and that disturbances in the renin-angiotensin and bradykinin levels and capillary leak have been observed with COVID19 infections. ACEI and ARB medications both modulate the renin angiotensin system, but with different impact on bradykinin levels. Changes in bradykinin levels cause for dry cough seen with ACE inhibitors like lisinopril that are not seen with angiotensin receptor blockers (ARB) such as Losartan. The absence of significant differences in outcome measures by holding either drug weakens the Jacobson’s bradykinin hypothesis based on a cascade of observations related to the ACE2 receptor and downstream effects. The new observations on safety of both ACEI and ARB weaken Jacobson’s hypothesis of a primary importance of renin angiotensin and bradykinin changes in the course and complications of COVID19 infection.

The ACE gene product degrades bradykinin. Jacobson’s bradykinin hypothesis suggested that the observations of capillary leak and disturbances in the renal angiotensin system may be prime factors rather than bystanders. Jacobson made strong statements from associations, but the lack of impact of stoppage of either ACE inhibitors or Angiotensin Receptor Blockers (ARB) argues that his observations are not major in determination of outcomes.

Bradykinin Hypothesis: Potential Explanation for COVID-19

The entry point for the virus is ACE2, which is a component of the counteracting hypotensive axis of RAS. Bradykinin is a potent part of the vasopressor system that induces hypotension and vasodilation and is degraded by ACE and enhanced by the angiotensin_1-9 produced by ACE2.

critical imbalance in RAS represented by decreased expression of ACE in combination with increases in ACE2, renin, angiotensin, key RAS receptors, kinogen and many kallikrein enzymes that activate it, and both bradykinin receptors. This very atypical pattern of the RAS is predicted to elevate bradykinin levels in multiple tissues and systems that will likely cause increases in vascular dilation, vascular permeability and hypotension. These bradykinin-driven outcomesexplain many of the symptoms being observed in COVID-19.

Jacobson says, “What we’ve found is that the imbalance in the renin-angiotensin system (RAS) pathway that appeared to be present in Covid-19 patients could be responsible for constantly resensitizing bradykinin receptors. So, this imbalance in the RAS pathways will take the brakes off the bottom of the bradykinin pathway at the receptor level. In addition, the downregulation of the ACE gene in Covid-19 patients, which usually degrades bradykinin, is another key imbalance in the regulation of bradykinin levels. We have also observed that the key negative regulator at the top of the bradykinin pathway is dramatically down-regulated. Thus, you likely have an increase in bradykin production as well, stopping many of the braking mechanisms usually in place, so the bradykinin signal spirals out of control.”

The bradykinin hypothesis also extends to many of Covid-19’s effects on the heart. About one in five hospitalized Covid-19 patients have damage to their hearts, even if they never had cardiac issues before. Some of this is likely due to the virus infecting the heart directly through its ACE2 receptors. But the RAS also controls aspects of cardiac contractions and blood pressure. According to the researchers, bradykinin storms could create arrhythmias and low blood pressure, which are often seen in Covid-19 patients.

“the pathology of Covid-19 is likely the result of Bradykinin Storms rather than cytokine storms,” which had been previously identified in Covid-19 patients, but that “the two may be intricately linked.”

According to Jacobson and his team, MRI studies in France revealed that many Covid-19 patients have evidence of leaky blood vessels in their brains.

bradykinin would indeed be likely to increase the permeability of the blood-brain barrier. In addition, similar neurological symptoms have been observed in other diseases that result from an excess of bradykinin.”

Increased bradykinin levels could also account for other common Covid-19 symptoms. ACE inhibitors — a class of drugs used to treat high blood pressure — have a similar effect on the RAS system as Covid-19, increasing bradykinin levels. In fact, Jacobson and his team note in their paper that “the virus… acts pharmacologically as an ACE inhibitor” — almost directly mirroring the actions of these drugs.

SOURCE

https://elifesciences.org/articles/59177?utm_source=Unknown+List&utm_campaign=7a5785d58d-EMAIL_CAMPAIGN_2020_07_27_02_37&utm_medium=email&utm_term=0_-7a5785d58d-

Potential therapeutic development path is to

• repurpose existing FDA approved drugs such as Danazol, Stanasolol, Icatibant, Ecallantide, Berinert, Cynryze, Haegarda, etc.. to reduce the amount of bradykinin signaling to prevent the escalation of the bradykinin storm.
• Partnerships with pharmaceutical companies and clinical research are needed to design and implement the right clinical trials to see how these types of treatments can be applied.
• Systems biology perspective and think that attempts to inhibit the virus itself will also probably require a combinatorial strategy it’s possible that we will need a combinatorial approach to therapies both on the human side and on the viral side
• Other compounds could treat symptoms associated with bradykinin storms. Hymecromone, for example, could reduce hyaluronic acid levels, potentially stopping deadly hydrogels from forming in the lungs. And timbetasin could mimic the mechanism that the researchers believe protects women from more severe Covid-19 infections

https://www.forbes.com/sites/cognitiveworld/2020/08/05/your-lungs-can-fill-up-with-jell-o-scientists-discover-a-new-pathway-for-covid-19-inflammatory-response/#7a80ff4c24be

 

A Supercomputer Analyzed Covid-19 — and an Interesting New Theory Has Emerged

A closer look at the Bradykinin hypothesis

Thomas Smith Sep 1, 2020

Earlier this summer, the Summit supercomputer at Oak Ridge National Lab in Tennessee set about crunching data on more than 40,000 genes from 17,000 genetic samples in an effort to better understand Covid-19. Summit is the second-fastest computer in the world, but the process — which involved analyzing 2.5 billion genetic combinations — still took more than a week.

When Summit was done, researchers analyzed the results. It was, in the words of Dr. Daniel Jacobson, lead researcher and chief scientist for computational systems biology at Oak Ridge, a “eureka moment.” The computer had revealed a new theory about how Covid-19 impacts the body: the bradykinin hypothesis. The hypothesis provides a model that explains many aspects of Covid-19, including some of its most bizarre symptoms. It also suggests 10-plus potential treatments, many of which are already FDA approved. Jacobson’s group published their results in a paper in the journal eLife in early July.

According to the team’s findings, a Covid-19 infection generally begins when the virus enters the body through ACE2 receptors in the nose, (The receptors, which the virus is known to target, are abundant there.) The virus then proceeds through the body, entering cells in other places where ACE2 is also present: the intestines, kidneys, and heart. This likely accounts for at least some of the disease’s cardiac and GI symptoms.

https://elemental.medium.com/a-supercomputer-analyzed-covid-19-and-an-interesting-new-theory-has-emerged-31cb8eba9d63

Researchers Use Supercomputers To Discover New Pathway For Covid-19 Inflammation

Jun WuContributor

COGNITIVE WORLD

Contributor Group

AI

A mechanistic model and therapeutic interventions for COVID-19 involving a RAS-mediated bradykinin storm

1. Michael R Garvin,
2. Christiane Alvarez,
3. J Izaak Miller,
4. Erica T Prates,
5. Angelica M Walker,
6. B Kirtley Amos,
7. Alan E Mast,
8. Amy Justice,
9. Bruce Aronow,
10. Daniel Jacobson

1. Oak Ridge National Laboratory, Biosciences Division, United States;
2. University of Tennessee Knoxville, The Bredesen Center for Interdisciplinary Research and Graduate Education, United States;
3. University of Kentucky, Department of Horticulture, United States;
4. Versiti Blood Research Institute, Medical College of Wisconsin, United States;
5. VA Connecticut Healthcare/General Internal Medicine, Yale University School of Medicine, United States;
6. University of Cincinnati, United States;
7. Biomedical Informatics, Cincinnati Children’s Hospital Research Foundation, United States;
8. University of Tennessee Knoxville, Department of Psychology, Austin Peay Building, United States

Abstract

Neither the disease mechanism nor treatments for COVID-19 are currently known. Here, we present a novel molecular mechanism for COVID-19 that provides therapeutic intervention points that can be addressed with existing FDA-approved pharmaceuticals. The entry point for the virus is ACE2, which is a component of the counteracting hypotensive axis of RAS. Bradykinin is a potent part of the vasopressor system that induces hypotension and vasodilation and is degraded by ACE and enhanced by the angiotensin_1-9 produced by ACE2.Here, we perform a new analysis on gene expression data from cells in bronchoalveolar lavage fluid (BALF) from COVID-19 patients that were used to sequence the virus. Comparison with BALF from controls identifies a critical imbalance in RAS represented by decreased expression of ACE in combination with increases in ACE2, renin, angiotensin, key RAS receptors, kinogen and many kallikrein enzymes that activate it, and both bradykinin receptors. This very atypical pattern of the RAS is predicted to elevate bradykinin levels in multiple tissues and systems that will likely cause increases in vascular dilation, vascular permeability and hypotension. These bradykinin-driven outcomes explain many of the symptoms being observed in COVID-19.

https://elifesciences.org/articles/59177?utm_source=Unknown+List&utm_campaign=7a5785d58d-EMAIL_CAMPAIGN_2020_07_27_02_37&utm_medium=email&utm_term=0_-7a5785d58d-

Short Report Jul 7, 2020

https://www.forbes.com/sites/cognitiveworld/2020/08/05/your-lungs-can-fill-up-with-jell-o-scientists-discover-a-new-pathway-for-covid-19-inflammatory-response/#7a80ff4c24be

A hypothesized role for dysregulated bradykinin signaling in COVID‐19 respiratory complications

Joseph A. Roche ¹ and Renuka Roche ²

Author information Article notes Copyright and License information Disclaimer

¹ Eugene Applebaum College of Pharmacy and Health Sciences, Wayne State University, Detroit MI, USA,

² College of Health and Human Services, Eastern Michigan University, Ypsilanti MI, USA,

Joseph A. Roche, Email: ude.enyaw@ehcor.hpesoj.

Corresponding author.

^*Correspondence
Joseph A. Roche, Eugene Applebaum College of Pharmacy and Health Sciences, Wayne State University, 259 Mack Ave., Detroit, MI 48201, USA.
Email: ude.enyaw@ehcor.hpesoj,

Abstract

As of April 20, 2020, over time, the COVID‐19 pandemic has resulted in 157 970 deaths out of 2 319 066 confirmed cases, at a Case Fatality Rate of ~6.8%. With the pandemic rapidly spreading, and health delivery systems being overwhelmed, it is imperative that safe and effective pharmacotherapeutic strategies are rapidly explored to improve survival. In this paper, we use established and emerging evidence to propose a testable hypothesis that, a vicious positive feedback loop of des‐Arg(9)‐bradykinin‐ and bradykinin‐mediated inflammation → injury → inflammation, likely precipitates life threatening respiratory complications in COVID‐19. Through our hypothesis, we make the prediction that the FDA‐approved molecule, icatibant, might be able to interrupt this feedback loop and, thereby, improve the clinical outcomes. This hypothesis could lead to basic, translational, and clinical studies aimed at reducing COVID‐19 morbidity and mortality.

Keywords: bradykinin, bradykinin receptor, coronavirus, icatibant, inflammation, injury

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7267506/

 

 

Kallikrein-kinin blockade in patients with COVID-19 to prevent acute respiratory distress syndrome

Frank L van de Veerdonk1*, Mihai G Netea1,2, Marcel van Deuren1,

Jos WM van der Meer1, Quirijn de Mast1, Roger J Bru¨ggemann3,

Hans van der Hoeven4

van de Veerdonk et al. eLife 2020;9:e57555. DOI: https://doi.org/10.7554/eLife.57555 1 of 9

Abstract

COVID-19 patients can present with pulmonary edema early in disease. We propose that this is due to a local vascular problem because of activation of bradykinin 1 receptor (B1R) and B2R on endothelial cells in the lungs. SARS-CoV-2 enters the cell via ACE2 that next to its role in RAAS is needed to inactivate des-Arg9 bradykinin, the potent ligand of the B1R. Without ACE2 acting as a guardian to inactivate the ligands of B1R, the lung environment is prone for local vascular leakage leading to angioedema. Here, we hypothesize that a kinin-dependent local lung angioedema via B1R and eventually B2R is an important feature of COVID-19. We propose that blocking the B2R and inhibiting plasma kallikrein activity might have an ameliorating effect on early disease caused by COVID-19 and might prevent acute respiratory distress syndrome (ARDS). In addition, this pathway might indirectly be responsive to anti-inflammatory agents.

 

Kinins and cytokines in COVID-19: a comprehensive pathophysiological approach

Frank L. van de Veerdonk1*, Mihai G. Netea1,2, Marcel van Deuren1, Jos W.M. van der Meer1, Quirijn de Mast1, Roger J. Brüggemann3, Hans van der Hoeven4

doi:10.20944/preprints202004.0023.v1

Abstract

Most striking observations in COVID-19 patients are the hints on pulmonary edema (also seen on CT scans as ground glass opacities), dry cough, fluid restrictions to prevent more severe hypoxia, the huge PEEP that is needed while lungs are compliant, and the fact that antiinflammatory therapies are not powerful enough to counter the severity of the disease. We propose that the severity of the disease and many deaths are due to a local vascular problem due to activation of B1 receptors on endothelial cells in the lungs. SARS-CoV-2 enters the cell via ACE2, a cell membrane bound molecule with enzymatic activity that next to its role in RAS is needed to inactivate des-Arg9 bradykinin, the potent ligand of the bradykinin receptor type 1 (B1). In contrast to bradykinin receptor 2 (B2), the B1 receptor on endothelial cells is upregulated by proinflammatory cytokines. Without ACE2 acting as a guardian to inactivate the ligands of B1, the lung environment is prone for local vascular leakage leading to angioedema. Angioedema is likely a feature already early in disease, and might explain the typical CT scans and the feeling of people that they drown. In some patients, this is followed by a clinical worsening of disease around day 9 due to the formation antibodies directed against the spike (S)-antigen of the corona-virus that binds to ACE2 that could contribute to disease by enhancement of local immune cell influx and proinflammatory cytokines leading to damage. In parallel, inflammation induces more B1 expression, and possibly via antibody-dependent enhancement of viral infection leading to continued ACE2 dysfunction in the lung because of persistence of the virus. In this viewpoint we propose that a bradykinin-dependent local lung angioedema via B1 and B2 receptors is an important feature of COVID-19, resulting in a very high number of ICU admissions. We propose that blocking the B1 and B2 receptors might have an ameliorating effect on disease caused by COVID-19. This kinin-dependent pulmonary edema is resistant to corticosteroids or adrenaline and should be targeted as long as the virus is present. In addition, this pathway might indirectly be responsive to anti-inflammatory agents or neutralizing strategies for the anti-S-antibody induced effects, but by itself is likely to be insufficient to reverse all the pulmonary edema. Moreover, we provide a suggestion of how to ventilate in the ICU in the context of this hypothesis.

 

Emerging Pandemic Diseases: How We Got to COVID-19

David M. Morens1,* and Anthony S. Fauci1

1Office of the Director, National Institute of Allergy & Infectious Diseases, National Institutes of Health, Bethesda, MD, USA

*Correspondence: dm270q@nih.gov

https://doi.org/10.1016/j.cell.2020.08.021

SUMMARY

Infectious diseases prevalent in humans and animals are caused by pathogens that once emerged from other animal hosts. In addition to these established infections, new infectious diseases periodically emerge. In extreme cases they may cause pandemics such as COVID-19; in other cases, dead-end infections or smaller epidemics result. Established diseases may also re-emerge, for example by extending geographically or by becoming more transmissible or more pathogenic. Disease emergence reflects dynamic balances and imbalances, within complex globally distributed ecosystems comprising humans, animals, pathogens, and the environment. Understanding these variables is a necessary step in controlling future devastating disease emergences.

Read Full Post »

Older Posts »

• Follow Blog via Email

  Enter your email address to follow this blog and receive notifications of new posts by email.

  Join 2,070 other followers

  Email Address:

  Follow

• Recent Posts

  • Fighting Chaos with Care, community trust, engagement must be cornerstones of pandemic response April 13, 2021
  • Linking Thrombotic Thrombocytopenia to ChAdOx1 nCov-19 Vaccination, AstraZeneca April 12, 2021
  • Cryo-EM disclosed how the D614G mutation changes SARS-CoV-2 spike protein structure. April 10, 2021
  • Embryogenesis in Mechanical Womb April 8, 2021
  • COVID-19 Sequel: Neurological Impact of Social isolation been linked to poorer physical and mental health March 30, 2021
  • T cells recognize recent SARS-CoV-2 variants March 30, 2021
  • Top Industrialization Challenges of Gene Therapy Manufacturing March 29, 2021
  • COVID-related financial losses at Mass General Brigham March 28, 2021
  • Consuming a higher amount of unprocessed red meat or poultry is associated with a lower risk of iron deficiency anemia: Outcome-wide analyses in 475,000 men and women in the UK Biobank study March 27, 2021
  • The WHO team is expected to soon publish a 300-page final report on its investigation, after scrapping plans for an interim report on the origins of SARS-CoV-2 — the new coronavirus responsible for killing 2.7 million people globally March 27, 2021

• Archives

  Archives Select Month April 2021  (4) March 2021  (15) February 2021  (17) January 2021  (20) December 2020  (10) November 2020  (12) October 2020  (26) September 2020  (17) August 2020  (22) July 2020  (27) June 2020  (33) May 2020  (26) April 2020  (42) March 2020  (22) February 2020  (11) January 2020  (7) December 2019  (20) November 2019  (13) October 2019  (11) September 2019  (3) August 2019  (8) July 2019  (25) June 2019  (47) May 2019  (40) April 2019  (27) March 2019  (29) February 2019  (17) January 2019  (50) December 2018  (14) November 2018  (17) October 2018  (18) September 2018  (17) August 2018  (8) July 2018  (20) June 2018  (22) May 2018  (17) April 2018  (12) March 2018  (20) February 2018  (26) January 2018  (16) December 2017  (6) November 2017  (20) October 2017  (13) September 2017  (16) August 2017  (16) July 2017  (19) June 2017  (20) May 2017  (32) April 2017  (21) March 2017  (10) February 2017  (24) January 2017  (21) December 2016  (43) November 2016  (8) October 2016  (40) September 2016  (67) August 2016  (59) July 2016  (75) June 2016  (37) May 2016  (95) April 2016  (152) March 2016  (175) February 2016  (196) January 2016  (139) December 2015  (90) November 2015  (287) October 2015  (237) September 2015  (115) August 2015  (96) July 2015  (63) June 2015  (44) May 2015  (53) April 2015  (76) March 2015  (95) February 2015  (83) January 2015  (75) December 2014  (75) November 2014  (88) October 2014  (135) September 2014  (117) August 2014  (88) July 2014  (88) June 2014  (109) May 2014  (60) April 2014  (85) March 2014  (58) February 2014  (72) January 2014  (107) December 2013  (104) November 2013  (136) October 2013  (62) September 2013  (32) August 2013  (46) July 2013  (74) June 2013  (110) May 2013  (112) April 2013  (86) March 2013  (92) February 2013  (63) January 2013  (63) December 2012  (46) November 2012  (71) October 2012  (84) September 2012  (82) August 2012  (122) July 2012  (59) June 2012  (34) May 2012  (46) April 2012  (2)

• Categories

  Categories Select Category 3D Printing for Medical Application  (212)    3D Plotting Scaffolds  (42)    BioInks  (33)       Biopolymer Blend Open Porous  (17)       Dental Applications  (10)    BioPrinting in Regenerative Medicine  (64)       Cell Level  (9)       MicroEngineering Cell-Tissue & Systems  (23)       Tissue Engineering  (32)    Cardiovascular and Vascular Systems  (23)       Artificial Vascular Structures  (7)       Cardiovascular Tissue  (7)    Drug Development using MultiOrgan Chip  (11)    Drug Development/Formulation using 3D Printing  (7)    MEMS  (14)       Bio-MEMS  (10)    Organ-on-a-Chip  (9)    Programmable Sensors (Carbon Nano Tubes)  (5) 3rd Party IP: Drug DIscovery  (1) 4D Printing and Meta Materials  (8) Academic Publishing  (212)    Key Opinion Leaders in eScientific Publishing – Interviews with  (6) Advanced Drug Manufacturing Technology  (88)    Antimalarial Preparation  (7)    Autologous Cell Therapy  (11)    Automated Cell Processing  (11) Allergy and Infectious Diseases  (10) Alzheimer’s Disease  (154)    Etiology  (75)    Medical Device Therapies for Altzheimer’s Disease  (13)    Pharmacotherapy and Cell Activity  (48) Anticancer Resistance  (27) Aortic Valve: TAVR  (3) Art Exhibits on the Human Condition  (1) Art Inspires Science  (3) Artificial Heart  (2) Artificial Intelligence – General  (125)    An executive’s guide to AI  (8)    Artificial Intelligence – Breakthroughs in Theories and Technologies  (63)    Artificial Intelligence Applications in Health Care  (60)       Artificial Intelligence in CANCER  (15)       Artificial Intelligence in Health Care – Tools & Innovations  (35)    Artificial Intelligence in Medicine – Application for Diagnosis  (39)       Artificial intelligence applications for cardiology  (20)          AI-assisted Cardiac MRI  (8)       Artificial Intelligence in Psychiatry  (5)       Deep Learning in Pathology  (10)    Artificial Intelligence in Medicine – Applications in Therapeutics  (29)    Machine Learning  (6)       Natural Language Processing (NLP)  (4) Auditory and vision  (11) Autism Spectrum Disorders  (10) Autoimmune Inflammatory DIseases  (17)    Crohn’s disease  (4)    Tolerance-inducing Autoimmune Disease Therapeutics  (2)    Ulcerative Colitis  (3) Autophagosome  (2) Bacterial Resistance  (23) Behavior  (22) Behavioral Genetics  (19) Big Data  (61)    Intelligent Information Systems  (37) Bio Instrumentation in Experimental Life Sciences Research  (359)    Analytical Instruments Industry  (3)    Microfuidics  (6) Bio-Ethics  (8) BioBanking  (29) Biodegradable Drug-eluting Material  (7) Bioengineering & reverse engineering design  (40) BioIT: BioInformatics  (116) BioIT: BioInformatics, NGS, Clinical & Translational, Pharmaceutical R&D Informatics, Clinical Genomics, Cancer Informatics  (94)    Advanced Computing Platform  (9)       Blockchain Transactions System  (1)    Pancreatic adenocarcinoma classifier  (3)    Simulation Modeling in NGS  (1) Biological Engineering  (35) Biological Networks  (175) Biological Networks, Gene Regulation and Evolution  (459)    Virology  (5) Biomarkers & Medical Diagnostics  (552)    VOC – Volatile Organic Compounds as BioMarkers  (1) Biomedical Measurement Science  (168) BioSimilars  (107) BioTechnology – Venture Creation  (118)    Foundations for supporting Science and Education  (12)    Philanthropy to Academic Institution  (2) BioTechnology – Venture Creation, Venture Capital  (99)    Seeking Talent  (3) BiVAD  (1) Blindness  (6) Bone Disease and Musculoskeletal Disease  (78) Brain Basis of Emotion  (4) Business Career Consideration  (1) Ca2+ triggered activation  (58) Calcium  (17) Calcium Signaling  (66) Calmodulin Kinase and Contraction  (33) Cancer – General  (160) Cancer and Current Therapeutics  (382)    interventional oncology  (39)       Breast Cancer – impalpable breast lesions  (17)       Prostate Cancer: Monitoring vs Treatment  (7) CANCER BIOLOGY & Innovations in Cancer Therapy  (1,059)    Anaerobic Glycolysis  (51)    Cachexia  (18)    Cancer Genomics  (52)       Circulating Tumor Cells (CTC)  (15)          Liquid Biopsy Chip detects an array of metastatic cancer cell markers in blood  (12)             mRNA  (4)          MagSifter chip  (1)       KRAS Mutation  (3)       Li-fraumeni syndrome.  (2)       TP53 – Germline mutations  (3)    cancer metabolism  (15)    Funding Opportunities for Cancer Research  (10)    Genomic Expression  (135)    Glioblastoma  (6)    Hexokinase  (14)    Loss of function gene  (14)    Metabolic Immuno-Oncology  (11)    Metastasis Process  (7)    Methylation  (29)    Microbiome and Responses to Cancer Therapy  (5)    Monoclonal Immunotherapy  (26)    mtDNA  (13)    Oxidative phosphorylation  (55)    Pancreatic cancer  (9)    Pyruvate Kinase  (27)    The NCI Formulary  (1)    tumor microenvironment  (10)    Warburg effect  (49) Cancer Informatics  (88) Cancer Prevention: Research & Programs  (124) Cancer Screening  (98) Cancer Vaccines: Targeting Cancer Genes for Immunotherapy  (23)    Engineering Enhanced Cancer Vaccines  (3) Cardiac and Cardiovascular Surgical Procedures  (288)    Aortic Valve: TAVR, TAVI vs Open Heart Surgery  (80)       Prosthesis-Patient Mismatch (PPM) in TAVI vs SAVR  (1)       TAVI vs Open Heart Surgery  (4)       Valve-in-Valve Procedure  (3)    Atrial Fibrilation (a-Fib), Cardiac Pacing and Arrhythmias  (12)    BackBeat’s Cardiac Neuromodulation Therapy (CNT) bioelectronic therapy  (1)    CABG  (43)    Cancer Surgery of the Heart  (10)    Cardiovascular Fluid Management: algorithms  (1)    Heart Transplant  (13)    Heart-Lung Transplant  (8)    Implantation  (1)    Left Main Coronary Artery Disease (LMCAD)  (3)    Mechanical Assist Devices: LVAD, RVAD, BiVAD, Artificial Heart  (19)    Mitral Valve: Repair and Replacement  (58)       TMVR – Transcatheter Mitral Valve Repair  (2)    PCI  (94)       Bioresorbable Vascular Scaffold (BVS)  (3)       Robotic-assisted percutaneous coronary intervention  (1)       Stent Retriever in endovascular thrombectomy  (1)    Peripheral Arterial Disease & Peripheral Vascular Surgery  (57)       Abdominal Aorta  (19)       Carotid Artery  (15)       Thoracic Aorta  (15)    Pulmonary Valve Replacement and Repair  (1)    Renal Denervation  (20)    Replacement  (1)    Tricuspid Valve Repair  (5)    Vena Caval Filters: Device for Prevention of Pulmonary Embolism and Thrombosis  (1) Cardiovascular Pharmacogenomics  (168) Cargo  (3) Cell Biology  (302) Cell Biology, Signaling & Cell Circuits  (638)    Apoptosis  (11)    Autophagy-Modulating Proteins  (3)    “Antibody–enzyme conjugates”  (3)    Cell Processing System in Cell Therapy Process Development  (16)    Endoplasmic reticulum  (2)    Enzymatic mechanism underlying the synthesis of adenosine triphosphate (ATP)  (1)    Ubiquitin  (5) Cerebrovascular and Neurodegenerative Diseases  (111)    Stroke  (3) Chemical Biology and its relations to Metabolic Disease  (454)    #BIGAxisSummit  (1)    Gut Microbiome and Obesity  (7) Chemical Genetics  (345) Child and Adolescent Psychiatry  (13) Childhood cancer  (12) Childhood malnutrition  (3) Circulating Progenitor Cells  (27)    Bone marrow derived cells  (17)    Endothelial cells  (7)    Umbilical cord cells  (6) Clinical & Translational  (231) Clinical Diagnostics  (208)    Mass automation of plasma proteins  (12) Clinical Genomics  (129) Coagulation Therapy and Internal Bleeding  (80) Cognition  (41) Commercialization  (19) Components and IRB related issues  (4) Computational Biology/Systems and Bioinformatics  (459)    Computational Histopathology  (1)    Meta-analysis of transcriptome data  (8) Conference Coverage with Social Media  (451)    MassBio  (3) coronavirus  (10) COVID-19  (11) CRISPR/Cas9 & Gene Editing  (178)    CRISPR alternative for editing genes without cutting  (12)       CAST – Alternative to CRISPR/Cas9  (3)       Transposon-encoded CRISPR–Cas systems direct RNA-guided DNA integration  (3)    CRISPR applied to Human Germ Line  (9)       Gene Editing Impact on Longevity  (4) CT  (18) Cytokines  (19) Cytoskeleton  (83) Developmental biology  (104) Diabetes Mellitus  (139)    Artificial Pancreas for Type1 Diabetes  (4)    Gestational diabetes  (2) Diagnostic Immunology  (53) Diagnostics and Lab Tests  (118)    Liquid Biopsy: Circulating Tumor Cells in Urine and Blood  (8) Digital HealthCare – biotech & internet joint ventures  (37) Disease Biology  (316) Disease Biology, Small Molecules in Development of Therapeutic Drugs  (476) DNA repair  (56)    Apoptosis  (11)    Autophagy  (10)    Cell death pathways  (15)    Proteolysis  (6)    Proteosome  (5) Drug Delivery Platform Technology  (146)    Drug Carrier Design  (15)       Medication Remote Compliance Monitoring  (3)    Exosomes: Natural Carriers for siRNA Delivery  (7) Drug Toxicity  (73) Ecosystems & Industrial Concentration in the Medical Device Sector  (172)    Cardiac & Vascular Repair Tools Subsegment  (128)    Exec Compensation in the Cardiac & Vascular Repair Tools Subsegment  (14)    Massachusetts Niche Suppliers and National Leaders  (20) Electronic Health Record  (8) Embryology  (24) Empathy  (6) Endocrine Diseases  (58) Enzyme Induction  (41)    ion-transporting enzyme  (1)    K + -ATPase.  (1)    Na +  (1) Epigenetics and Environmental Factors  (22) Ethics and Leadership  (9) Executive Compensation – Big Pharma  (3) Fat soluble vitamins  (4) FDA  (64) FDA Regulatory Affairs  (350)    FDA, CE Mark & Global Regulatory Affairs: process management and strategic planning – GCP, GLP, ISO 14155  (50)    ISO 10993 for Product Registration: FDA & CE Mark for Development of Medical Devices and Diagnostics  (30) Fetal Ultrasound  (1) Fiction and medicine  (4) Frontiers in Cardiology and Cardiovascular Disorders  (820)    Acute Myocardial Infarction  (48)       Cardiogenic Shock  (3)    Anemia in CVD Patients  (6)    Cardio-Oncology  (3)    Cardiomyopathy  (53)    Cardiovascular Research  (162)       Myocardial metabolism, Myocardial ischemia, Myocardial adenine nucleotide metabolism  (43)       Pre-Clinical Animal Model Development  (23)    Chronic Thromboembolic Pulmonary Hypertension (CTEPH) and Pulmonary Arterial Hypertension (PAH)  (19)    Cost of Inpatient Stay for Cardiovascular Diagnosis for Admission  (1)    Electrophysiology  (99)       Ablation Procedure vs Drug Therapy  (1)       Arrhythmia Detection with Machine Learning Algorithms  (5)       Cardiotoxic Risks of Immune Checkpoint Inhibitors  (1)       Genomic Analysis of EKG Electrophysiology Genomics  (2)       implantable cardioverter defibrillator (ICD) and External Defibrillation  (1)       implantable pacemaker  (2)       Rare heart rhythm disorders and Long QT syndrome (LQTS)  (5)    Epigenetics and Cardiovascular Risks  (54)    Heart Failure (HF)  (33)       Acute coronary syndrome  (5)       congestive heart failure  (17)    Medical Devices R&D and Inventions  (201)       Assist Devices: LV  (3)       RV  (1)       Stents & Tools  (87)       Valves & Tools  (63)    Origins of Cardiovascular Disease  (401)       Atherogenic Processes & Pathology  (166)       Congenital Heart DIsease  (34)          Genetic Mutations in Congenital Heart DIsease  (4)       inflammation independent of lipid levels  (10)       Systemic Inflammatory Diseases as CVD Risk  (9)    Pharmacotherapy of Cardiovascular Disease  (328)       HTN  (155)       HTN in Youth  (7)       Resident-cell-based  (42)       Subarachnoid Hemorrhage (SAH)  (1)       Transthyretin amyloid cardiomyopathy (ATTR-CM)  (1)    Spontaneous Coronary Artery Dissection (SCAD)  (6)    Stroke  (6)       endovascular thrombectomy  (2)    Vascular Diseases  (11) Future Pandemics Inform-graphics  (1) Gastroenterology  (36) Gene Regulation  (218) Gene Regulation and Evolution  (130) Genetics & Innovations in Treatment  (160) Genetics & Pharmaceutical  (192) Genome Biology  (926)    Exosomes  (21)    Gene Therapy & Gene Editing Development  (31)    mRNA Therapeutics  (14)    Mutagenesis  (24)    Single Cell Genomics  (20)    Single-cell sequencing  (14)    Variation in human protein-coding regions  (22) Genomic Endocrinology  (38) Genomic Testing: Methodology for Diagnosis  (408) Genomics Pharmacy  (36) Global Market of Medical Devices Technology  (1) Global Medical Publishers by Country  (1) Global Partnering & Biotech Investment  (43) GLP  (4) Glycobiology: Biopharmaceutical Production  (12) Glycobiology: Biopharmaceutical Production, Pharmacodynamics and Pharmacokinetics  (25) Health Care System by Country  (32)    Centers for Medicare & Medicaid Services  (5)    Health in Israel  (1)    United States  (16)       Hospital-based Medical Innovations  (7)       Medical Recertification and Maintenance of Certification (MOC)  (1) Health Economics and Outcomes Research  (369)    Women Health  (10)       Heart and Brain Disease in Women  (3) Health Law & Patient Safety  (154)    and Bioethics  (10)    Biotechnology  (8)    Health Law Policy  (5) HealthCare IT  (126) Healthcare Reform  (104)    Accountable Care Organizations  (24)    Affordable Care Act  (28)       Repair  (1)       Repeal ACA  (1)       Replace  (1)    Federal Budget Appropriations  (23)    Healthcare costs and reimbursement  (52)    Indigent Nutrition  (13)    Medicare and Medicaid  (20)    Prescription Drugs Costs  (19)    Skilled Nursing Facilities  (6)    Technology Capital Expenses  (14)    Uninsured and Underinsured  (19) Hematology  (96)    Acute lymphocytic leukemia  (18)    Acute myelocytic leukemia  (21)    Hematopoiesis  (48)    Lymphoma  (21) History and physical exam  (6) Human aging  (26) Human Immune System in Health and in Disease  (232) Human Sensation and Cellular Transduction: Physiology and Therapeutics  (20) Image Processing/Computing  (40) Imaging-based Cancer Patient Management  (116) Immuno-Oncology & Genomics  (119)    mRNA platform in Drug DIscovery  (5) Immunodiagnostics  (121)    Cancer-Immune Interactions  (16)    CNS-Immune Interface  (3)    Neuronal Circuits  (4) Immunology  (98)    Adaptive Immune Response to Biomaterials and Tissue Repair  (8)    Antibody Responses Predict Antigen Exposure  (10)    Cytokine Receptor Structure  (6)    Human Antibody Response  (13)    Human Circulating Antibody Repertoire  (9)    Human Naive B Cell Repertoire  (8)    MHC Repertoires for Antigen Prediction  (8)    Protection Against Autoimmune Disease  (7)    Synthetic Immunology: Hacking Immune Cells  (12) Immunotherapy  (110)    CAR-T  (13)    combination immunotherapies.  (10)    Efficacy of Anti-Tumor T Cells  (8)    Engineering Better T Cells  (7)    Immune Engineering  (12)    Immune Modulatory  (11)    Integrin-targeted Combination Immunotherapy  (5)    Modulating Macrophages in Cancer Immunotherapy  (10)    NK Cell-Based Cancer Immunotherapy  (14)    Synergistic Innate and Adaptive Immunotherapy  (12) Income Disparity  (2) Infectious Disease & New Antibiotic Targets  (148)    Antibiotic resistance  (4)    Viral diseases  (27) Infectious Disease Immunodiagnostics  (46)    Virology – Vector-borne DIsease  (12) Inflammasome  (26)    Anti-tumor necrosis factor drugs (TNF inhibitors)  (2) Innovation in Immunology Diagnostics  (102)    Universal Immune Cell Therapies (uICT)  (8) Innovations  (173)    R&D Expenditure  (2) Innovations in Neurophysiology & Neuropsychology  (131)    Age and Life Expectancy  (1)    autism spectrum disorder  (1)    Circadian Rhythm and Sleep  (6)    hNPCs  (1)    Nervous System Function  (1)    Relapsing Multiple Sclerosis  (1) Intellectual Property  (72)    Disputes and Settlements  (8)    IP Valuation Models – Pricing Intangible Assets  (3)    Patent Law in Biotech  (11) Intellectual Property, Innovations, Commercialization, Investment in technological breakthrough  (102) International Global Work in Pharmaceutical  (187) Interventional Oncology: Radiofrequency Ablation, Transarterial Chemoembolization, Microwave Ablation and Irreversible Electroporation (IRE)  (12) Interviews with Scientific Leaders  (283)    Albany Medical Center Prize in Medicine and Biomedical Research  (1)    Annual Breakthrough Prize  (2)    Annual Lewis S. Rosenstiel Award  (1)    Awards in Cardiology and Cardiovascular Medicine  (3)    CEOs of Biotech Companies  (1)    Gerald D Aurbach Award for Outstanding Translational Research  (1)    Interviews with Key Opinion Leaders (KOLs)  (6)    James Prize in Science and Technology Integration  (1)    Jessie Stevenson Kovalenko Medal – Medical Sciences  (1)    Lemelson-MIT Prize  (1)    Life Sciences Breakthrough Prize  (2)    Mosteller Statistician of the Year Award  (1)    Mourning the Loss of a Scientific Leader  (2)    National Academy of Sciences AWARDS  (2)    Nobel Prize WInners  (15)    Noble Prize (Not Nobel Prize)  (1)    Paul Marks Prize for Cancer Research  (1)    Russ Prize recognizes bioengineering achievements worldwide  (1)    The Dan David Prize  (5)    Warren Alpert Foundation Prize Recipients  (3)    Wolf Prize  (1)    Wolf Prize in Medicine  (1)    women in science  (3) Investment in Technological Breakthrough  (56) Ionic Transporters Na+  (25) IP Development by LPBI Group Team  (8) IP Development by LPBI Group Team & Other Organizations  (5) ISO 14155  (3) Joint Venture – SBH & M3DP: SOP and Arrangements  (1) Justice & Law  (1) K  (15) Lab-on-a-chip  (2) Landscape  (1) Lasers and photonics  (18)    Midrange IR spectroscopy  (1) Law and Medicine Conflicts  (12) Leadership, Power, Social Interlocking Connections  (12) Lipid metabolism  (108)    Fatty acids  (37)    Lipids  (37)    PCSK9 Inhibitor Therapy  (19) Lipidomics  (10) Liposome  (3) Liver & Digestive Diseases Research  (117) LPBI Group, e-Scientific Media, DFP, R&D-M3DP, R&D-Drug Discovery, US Patents: SOPs and Team Management  (109)    Award Nominations  (5)    BioMed e-Books e-Series by LPBI Group  (6)    Feedback from Investors: LPBI Portfolio of Five Businesses  (2)    LPBI Group Founder – Aviva Lev-Ari  (16)    PhD  (1)    RN  (1) LPBI Management  (5) Massachusetts Academy of Sciences (MAS)    (2) Materials Science & Engineering  (31) Math  (13)    Great Discoveries  (7) Mechanical Assist Devices: LVAD  (4) Medical and Population Genetics  (190) Medical Devices R&D Investment  (234)    21st Century Cures Act  (2)    CE Mark & Global Regulatory Affairs: process management and strategic planning – GCP  (13)    Rhythm management device hardware: dual-chamber pacemakers  (1)       Systolic HTN  (1) Medical Imaging Technology  (51) Medical Imaging Technology, Image Processing/Computing, MRI, CT, Nuclear Medicine, Ultra Sound  (150)    Circumferential-Intravascular-Radioluminescence-Photoacoustic-Imaging (CIRPI)  (2)    Invasive FFR for PCI  (2)    MRI  (15)    Noninvasive Diagnostic Fractional Flow Reserve (FFR) CT  (4)    Ultra Sound  (7) Melatonin & Circadian Regulation  (7) Metabolism  (229)    Biochemical pathways  (137)       Enzymes and isoenzymes  (69)          Dehydrogenase  (14)          Kinase  (27)          Phosphatase  (8)          Phosphorylase  (21)          tyrosine decarboxylases  (2)    Inosine nucleotides  (8)    Leloir pathway  (6)    microbiome  (6)    Pentose monophosphate shunt  (14)    Pyridine nucleotides  (28)       Pyridine nucleotide transhydrogenase  (7) Metabolomics  (315) Methods  (37) Mg++  (10) Microbiologial genetics  (31) Microbiology  (58)    Virology  (10) Micronutrients  (15) Microvesicle  (6) Microwave Ablation and Irreversible Electroporation (IRE)  (1) Mobile Healthcare  (1) Molecular Genetics & Pharmaceutical  (371)    Organoids  (3) Monoclonal antibody therapy  (7) Mutant Gene Expression  (38) Myocardial adenine nucleotide metabolism  (5) Myocardial Ischemia  (24) Myocardial Metabolism  (34) Na-K transport  (39) Na-K-ATPase  (26) Nanotechnology for Drug Delivery  (89) Nephrology  (45) Nephrology & Regenerative medicine  (8) Neurodegenerative Diseases  (81)    hNPCs  (3)    MS  (4) Neurohumoral Transmission  (64)    Ca2+ triggered activation  (18)    Calmodulin  (11)    Parkinson’s disease dyskinesia levodopa  (2)    PKC  (13)    Synaptic vesicle  (19) Neurological Diseases  (115) Neuroscience  (119) Next Generation Sequencing (NGS)  (18)    Nanopore sequencing  (1) NIH Common Fund  (1) Nitric Oxide in Health and Disease  (135) Nuclear Medicine  (11) Nutrigenomics  (67) Nutrition  (192)    Nutritional Supplements: Atherogenesis, lipid metabolism  (47) Nutrition and Phytochemistry  (59)    Minerals in Medicine  (4)    Plant extract  (21) Nutrition Disorders  (29) Nutritional Supplements: Atherogenesis  (30) Obesity  (17) Oligonucleotide Therapeutics & Delivery  (5) Oncolytic virus & OncoViro-Therapy  (18)    Synthetic Virology  (1) Organ-on-a-Chip & 3D Printing in Life Sciences  (7) Pain: Etiology, Genetics & Innovations in Treatment  (22) Parasitology  (5)    Malaria  (4)    Tropical diseases  (1) Patents  (32) Patient Experience  (61)    Art therapy  (1)    Hospital reputation  (6)    Humor  (1)    Music therapy  (2)    Pain Alleviation  (7)    Patient Outlook  (27)    Reputation of Interventionist  (4)    Support Staff  (12)    Supportive therapies  (6)       laughfter  (1)    Surgical Procedure  (7) Patient Experience: Personal Memories of Invasive Medical Intervantion  (30) Patient’s Voice: Personal Experience with Invasive Medical Procedures  (18) Perioperative Statins at Noncardiac Surgery  (1) Personal Health Applications: Tech Innovations serves HealhCare  (31) Personalized and Precision Medicine & Genomic Research  (701)    Longevity  (1)    New Drug Approval  (1)    Patient-centered Medicine  (28)       cell-based therapy  (6)       stem cell biology and patient-specific  (6)    Personalized Medicine Coalition  (6)    Precision Cancer Medicine  (14) Phagophore  (1) Pharmaceutical Analytics  (258)    Pharmacologic toxicities  (61) Pharmaceutical Discovery  (100)    Rapid automation of plasma protein pools  (16) Pharmaceutical Drug Discovery  (180)    Drug Development Process  (39)       Drug Discovery Chemistry  (19)    drug repurposing  (7) Pharmaceutical Industry Competitive Intelligence  (331)    Pharmacovigilance  (5)    Value-based Drug Pricing  (7) Pharmaceutical R&D Informatics  (41) Pharmaceutical R&D Investment  (297) Pharmacodynamics and Pharmacokinetics  (20) Pharmacogenomics  (154) Photography Collection  (1) Physics  (12) Placenta  (6) Population genetics  (25) Population Health Management  (178)    Evolution of Biology Through Culture  (12)    U.S. Employment-to-Population Ratio  (7) Population Health Management, Genetics & Pharmaceutical  (592)    COVID-19  (136)       Biomarkers: Inflammation  (31)       Cancer Researchers Fighting COVID-19  (12)       COVID-19 effects on Human Heart  (11)       COVID-19: Pandemic Surgery Guidance  (17)       Economic Impact of Coronavirus Pandemic  (41)       number of asymptomatic infections  (24)       Treatment Protocols for COVID-19  (51)    SARS-CoV-2  (118)       Coronavirus Gene Expression  (50)          SARS-CoV-2 circulating variants   (4)          SARS-CoV-2 Viral Variants  (5)       Glycosylation and its Role in SARS-CoV-2 Viral Pathogenesis  (1)       Immune-Mediation (independent immunopathology: lung and reticuloendothelial system)  (23)       Mechanisms of infection by SARS-CoV-2  (9)       SAR-Cov-2 a vasculotropic (blood vessels) RNA Virus  (28)          SARS-COV2 Hijacking the Complement and Coagulation Systems  (14)       Seasonality & Environmental Factors in Resurgence  (26)       Serology tests for coronavirus antibodies  (42)       T-cell response to SARS-CoV-2 infection  (6)       Vaccinology  (38)       Virtual Drug Molecule Screening targeting SAR-CoV-2 proteins  (4)    Virus Infective Acute Respiratory Syndrome: SARS-CoV  (83) Population Health Management, Nutrition and Phytochemistry  (149) Preimplantation Genetic Diagnosis and Reproductive Genomics  (9) Protein-energy malnutrition  (11) Proteomics  (352)    Amino acids  (49)    Proteins  (128) Pulmonary diseases  (14)    Lung and pulmonology  (13) Pulmonary pathology  (6) Radio Frequency (RF)-based Surgical Solutions  (2) REAL TIME Conference Coverage Twitter’s Hashtags and Handles per Presentation/session  (28) Regenerative Biology and Medicine  (82) Regulated Clinical Trials: Design, Methods, Components and IRB related issues  (263) Reproductive Andrology, Embryology, Genomic Endocrinology, Preimplantation Genetic Diagnosis and Reproductive Genomics  (102) Reproductive Biology & Bio Instrumentation  (68) RNA Biology  (72)    RNA interference (RNAi) therapeutic  (4) RNA Biology, Cancer and Therapeutics  (56) RVAD  (1) SBIR, SBA, NIH, NSF  (2) Schizophrenia  (14) Scientific & Biotech Conferences: Press Coverage  (170) Scientific Publishing  (600)    Curation  (580)       Curation methodology  (37)       De novo synthesis  (15)       Dialectic  (17)       Discovery process  (69)       Evolutionary cognition  (53)       Experimental validation  (90)       Explanatory  (92)       Historical relevance  (71)       Technology Advance Assessment of  (67)       Theoretic convergence  (27)    Open Access Journals  (31) Scientist: Career considerations  (190)    Big Data & Analytics  (12)    Data Science  (9)    Women in Life Sciences  (10) Scoop.it  (18) Sensors & Analytics  (16) Sepsis  (2) Severe Autism  (3) Signaling  (94)    Phosphorylation  (40)    S-nitrosylation  (11)    Ubiquitinylation  (30) Signaling & Cell Circuits  (123) Small Molecules in Development of Therapeutic Drugs  (65) Social Development  (15) Specialized 3D BioPrinters (Cornea  (1) Statistical Methods for Research Evaluation  (136) Stem Cells for Regenerative Medicine  (171)    Cardiac muscle regeneration  (17)    Competition in regenerative stem cell science  (17)    Human neural progenitor sells  (6)    Skeletal muscle regeneration  (8) STORM  (2) Stress Disorders  (18) Substance Abuse  (4) Systemic Inflammatory Response Related Disorders  (156)    Inflammatory Pathophysiology  (4) Technology Transfer: Biotech and Pharmaceutical  (347) Tissue Engineering and Regenerative Medicine  (20) Tissue Microenvironment  (3) Transarterial Chemoembolization  (2) Transcriptomics  (41) Transformative Technologies in Healthcare  (9) Translational Science  (215)    Best evidence  (52)    Bias measurement tools  (2)    Evidence-based decision-making  (26)    Inferential analysis  (25)    Intra-rater error  (1)    Quality Assurance  (8)    Random Error  (2)    Systematic Error (Bias)  (5)    Total error  (2)    Translational Effectiveness  (49)    Translational Research  (84) Trends in Global Economy  (3) Uncategorized  (1,326) Unfolded Protein Response (UPR)  (4) US and Global Economy: Trends and Findings  (6) Venture Capital  (41)    Income Geographic Distribution  (2)    Institutional Capital Raised by Female Founders  (4) virology  (2) Vision  (6) Voices of Patients and Healthcare Providers  (19) Water Transporters  (7) Wearable Tech + Digital Health  (3) Anemia  (21) Neutropenia  (8) Neutrophilia  (9) Platelet count disorder  (9) Folate and B12  (7) Iron deficiency  (5) Myelodysplasia  (12) Myelofibrosis  (10)

• Meta

  • Register
  • Log in
  • Entries feed
  • Comments feed
  • WordPress.com

• • 2012pharmaceutical
  • Amandeep Kaur
  • Aashir Awan, Phd
  • Adina Hazan
  • Alan F. Kaul, PharmD., MS, MBA, FCCP
  • alexcrystal6
  • anamikasarkar
  • apreconasia
  • aviralvatsa
  • David Orchard-Webb, PhD
  • danutdaagmailcom
  • Demet Sag, Ph.D., CRA, GCP
  • Daniel Menzin
  • Dror Nir
  • dsmolyar
  • evelinacohn
  • Gail S Thornton
  • Irina Robu
  • jayzmit48
  • jdpmd
  • jshertok
  • kellyperlman
  • Ed Kislauskis
  • larryhbern
  • Madison Davis
  • marzankhan
  • megbaker58
  • ofermar2020
  • Dr. Pati
  • pkandala
  • Rosalind Codrington, PhD
  • ritusaxena
  • Rick Mandahl
  • sjwilliamspa
  • stuartlpbi
  • Dr. Sudipta Saha
  • tildabarliya
  • zraviv06
  • zs22